Home/Publication/Qiming & OrbiMed Join Morningside in Gene Therapy
Qiming & OrbiMed Join Morningside in Gene Therapy 

31 Aug 2023

US$ 19.00

Qiming Venture Partners and OrbiMed Advisor LLC have co-led the US$32 million series A funding round of Epigenic...

Price / article: US$19.00
OR existing subscriber
Related Publications

Granite Asia has led a US$60 m series A funding round in the US-based Centific Global Solutions Inc (Centific), an AI...

Connect With Us

We love to share Asia PE insights and news from time to time. Drop us your email address if you like to hear from us.

Rest assured that your email address will not be shared, as we hate spams as much as you do.